Tadalafil, a further innovation in the treatment of sexual dysfunction

Drugs of Today

Volumn 39, Issue 2, 2003, Pages 103-113

  Pomerol, José María ^a   Rabasseda, Xavier ^b  

^a FUNDACIÓ PUIGVERT   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; BMS 341400; E 8010; EMD 221829; FR 229934; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL; TA 1790; TADALAFIL; UDENAFIL; UK 343664; UK 357903; UNCLASSIFIED DRUG; VARDENAFIL;

ADULT; AGED; ANIMAL CELL; AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FEMALE; HEADACHE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MYALGIA; NONHUMAN; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RAT; REVIEW; SEXUAL DYSFUNCTION; SINGLE BLIND PROCEDURE;

AREA UNDER CURVE; CARBOLINES; FEMALE; HALF-LIFE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; SEXUAL AND GENDER DISORDERS;

EID: 0037321950     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.2.799417     Document Type: Review

References (39)

1. Sorbera, L.A., Martín, L., Leeson, P.A., Castañer, J. IC-351. Drugs of the Future 2001, 26: 15-9.
2. Prous Science Drug R & D Backgrounders: Male and female sexual dysfunction (online publication). Updated Jan 8, 2000.
3. Benet, A.E., Melman, A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995, 22: 699-709.
4. Moreland, R.B., Hsieh, G., Nakane, M., Brioni, J.D. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol and Exper Ther 2001, 296: 225-34.
5. Pryor, J.L., Redmon, B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int J Impotence Res 2000, 12 (Suppl. 4): S158-62.
6. Corbin, J.D., Francis, S.H. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem 1999, 274: 13729-32.
7. Daugan, A.C.-M. (ICOS Corp.). Use of cGMP-phophodiesterase inhibitors to treat impotence. JP 199509221, US 6140329, WO 9703675.
8. th Annual Meeting of the European Association for the Study of Diabetes (EASD), 2001, Glasgow, Scotland, UK; poster.
9. th Congress of the European Society for Sexual and Impotence Research (ESSIR), 2001, Rome, Italy; poster.
10. th Congress of the European Society for Sexual and Impotence Research (ESSIR), 2001, Rome, Italy; poster.
11. th Annual Meeting of the American Urological Association (AUA), 2001, Anaheim, California, USA; poster.
12. rd Meet Eur Soc Impot Res Barcelona, Spain 2000, 7.
13. Guiliano, F., Meuleman, E., Saoud, J., Ferguson, K., Whitaker, S., Porst, H. Daily IC351 treatment of erectile dysfunction. Eur Urol 2000, 37 (Suppl. 2): Abst 320.
14. Padma-Nathan, H., McMurray, J., Saoud, J. et al. On-demand treatment of erectile dysfunction with IC351. Eur Urol 2000, 37 (Suppl. 2): Abst 319.
15. Anglin, G., Iglesias, J., Toulouse, K., Saoud, J., Pullman, W., Brock, G. Efficacy and safety of IC351 treatment for erectile dysfunction. Int J Impot Res 2000, 12 (Suppl. 3): Abst B8.
16. th Congress of the European Society for Sexual and Impotence Research (ESSIR), 2001, Rome, Italy; poster.
17. ICOS Science. ICOS Web Site.
18. Carrier, S., McMahon, C., Chen, K.K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. J Urol 2002, 167 (4, Suppl.): Abst 713.
19. Patterson, D., McDonald, T.M., Effron, M.B. et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Int J Impot Res 2002, 14 (Suppl. 3): Abst CP5.48.
20. Hellstron, W., Overstreet, J., Yu, A., Shen, W., Beasley, C., Watkins, V. Tadalafil has no effect on semen characteristics. Int J Impot Res 2002, 14 (Suppl. 3): Abst C4.9.
21. Kloner, R.A., Emmick, J., Bedding, A., Humen, D. Pharmacodynamic interactions between tadalafil and nitrates. Int J Impot Res 2002, 14 (Suppl. 3): Abst C4.8.
22. Patterson, B., Bedding, A., Jewell, H., Payne, C., Mitchell, M. Dose-normalized pharmacokinetics of tadalafil administered as a single dose to healthy volunteers. BJU Int 2002, 90 (Suppl. 2): Abst P-3.2.17.
23. Patterson, D., MacDonald, T.M., Effron, M.B., Emmick, J.T., Mitchell, M.I. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002, 106 (Suppl. 2): Abst 1650.
24. Patterson, B., Bedding, A., Jewell, H., Payne, C. Mitchell, M. Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers. Eur Urol Suppl 2002, 1: Abst 600.
25. Gbekor, E., Bethell, S., Fawcett, L., Mount, N., Phillips, S. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J Urol 2002, 167 (4, Suppl.): Abst 967.
26. Kloner, R.A., Watkins, V., Costigan, T., Bedding, A., Mitchell, M., Emmick, J. Cardiovascularprofile of tadalafil, a new PDE5 inhibitor. Int J Impot Res 2002, 14 (Suppl. 3): Abst C5.4.
27. Chen, K.K., Hsieh, J.T., Wang, C.J., Jiaan, D.B.P., Lin, J.S.N., Lee, S.S. Efficacy and safety of on-demand oral tadalafil in Taiwanese men with erectile dysfunction. Int J Impot Res 2002, 14 (Suppl. 3): Abst CP5.21.
28. Brock, G., McMahon, C., Chen, K.K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. Int J Impot Res 2002, 14 (Suppl. 3): Abst CP5.22.
29. Kloner, R.A., Watkins, V.S., Costigan, T.M., Bedding, A., Mitchell, M.I., Emmick, J. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. J Hypertens 2002, 20 (Suppl. 4): Abst P1053.
30. Hutter, A.M., Kloner, R.A., Watkins, V. et al. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor. Am J Hypertens 2002, 15 (4, Part 2): Abst P-302.
31. Padma-Nathan, H., Brock, G., McMahon, K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Am J Hypertens 2002, 15 (4, Part 2): Abst P-313.
32. Chang, S., Mitchell, M.I., Bedding, A.W., Emmick, J.T., Kloner, R.A. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil J Am Coll Cardiol 2002, 39 (9, Suppl. B): 12B.
33. McMahon, C.G., Brock, G.B., Cen, K.K. et al. Tadalafil significantly improves erectile function in men with ED: Integrated analysis of registration trials. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 43B.
34. Brock, G., McMahon, C., Chen, K.K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. J Urol 2002, 167 (4, Suppl.): Abst. 713.
35. Porst, H., Rosen, R.C., Padma-Nathan, H., Varanese, L., Anglin, G., Giuliano, F. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol 2002, 167 (4, Suppl.): Abst. 709.
36. Kloner, R.A., Watkins, V.S., Costigan, T.M., Bedding, A., Mitchell, M.I. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. J Urol 2002, 167 (4, Suppl.): Abst. 707.
37. Venugopalan, M., Brock, G., McMahon, C., Chen, K.K., Watkins, V., Whitaker, J.S. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. Int J Urol 2002, 9 (Suppl.): Abst. 16
38. Carrier, S., McMahon, C., Chen, K.K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. BJU Int 2002, 90 (Suppl. 2): Abst. P-3.2.04.
39. Carrier, S., Watkins, V., Costigan, T., Bedding, A., Mitchell, M., Emmick, J. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. BJU Int 2002, 90 (Suppl. 2): Abst. PD-2.08.